Appendix 4E & Full Year Statutory Accounts
Filed with ASX · · 72 pages · English
Summary by 6ix AI
The report indicates a significant loss for the company, contrasting with a profit in the previous year, and highlights that no dividends were declared during the period. The filing also discusses the company's strategic growth, including the acquisition of TrialsWest and advancements in its software-as-medical-device technologies. Overall, the report emphasizes the company's commitment to innovation and operational excellence as it prepares for future growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Resonance Health
- TrialsWest Expands with New Clinical Trial Site
- Half Yearly Report and Accounts
- Non-deal Investor Roadshow Presentation
- Resonance Contracted by Major Global Pharma
- Trading Halt
Later from Resonance Health
- Investor Strategy Day Presentation
- AGM Presentation
- Quarterly Activities/Appendix 4C Cash Flow Report
- Half Year Report & Accounts
- Half Year Results
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health